Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CARMNASDAQ:DWTXNASDAQ:MBRXNASDAQ:TNFA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCARMCarisma Therapeutics$0.45-17.6%$0.23$0.14▼$1.90$18.87M1.633.72 million shs12.42 million shsDWTXDogwood Therapeutics$4.65-10.2%$4.85$1.62▼$29.28$8.89M1.881.63 million shs51,671 shsMBRXMoleculin Biotech$0.64-4.0%$0.90$0.40▼$4.90$9.07M1.561.53 million shs305,294 shsTNFATNF Pharmaceuticals$0.14-10.6%$0.20$0.13▼$2.16$1.94M2.061.33 million shs3.83 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCARMCarisma Therapeutics-9.12%+194.73%+195.05%+33.38%-53.15%DWTXDogwood Therapeutics+7.47%+5.93%+6.80%-15.36%+517,999,900.00%MBRXMoleculin Biotech-3.05%-3.13%-37.52%-40.84%-84.53%TNFATNF Pharmaceuticals-6.76%-4.01%-14.27%-58.37%+15,319,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCARMCarisma Therapeutics3.3324 of 5 stars3.25.00.00.02.51.71.3DWTXDogwood Therapeutics2.0114 of 5 stars3.50.00.00.02.00.01.3MBRXMoleculin Biotech3.3348 of 5 stars3.55.00.00.03.30.01.3TNFATNF PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCARMCarisma Therapeutics 2.43Hold$1.93326.26% UpsideDWTXDogwood Therapeutics 3.00Buy$10.00115.05% UpsideMBRXMoleculin Biotech 3.00Buy$4.00523.05% UpsideTNFATNF Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TNFA, CARM, MBRX, and DWTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2025MBRXMoleculin BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$4.004/23/2025DWTXDogwood TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$10.004/1/2025CARMCarisma TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $1.003/25/2025MBRXMoleculin BiotechMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$4.003/24/2025MBRXMoleculin BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCARMCarisma Therapeutics$19.96M0.95N/AN/A$0.66 per share0.68DWTXDogwood TherapeuticsN/AN/AN/AN/A$4.94 per shareN/AMBRXMoleculin BiotechN/AN/AN/AN/A$11.70 per shareN/ATNFATNF PharmaceuticalsN/AN/AN/AN/A$7.21 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCARMCarisma Therapeutics-$86.88M-$1.56N/AN/AN/A-314.78%-957.20%-96.39%8/6/2025 (Estimated)DWTXDogwood Therapeutics-$5.30M-$18.04N/AN/AN/AN/A-217.12%-172.06%8/6/2025 (Estimated)MBRXMoleculin Biotech-$29.77MN/A0.00N/AN/AN/A-157.44%-97.16%8/4/2025 (Estimated)TNFATNF Pharmaceuticals-$4M-$6.67N/A∞N/AN/A-180.71%-84.27%8/18/2025 (Estimated)Latest TNFA, CARM, MBRX, and DWTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025TNFATNF PharmaceuticalsN/A-$0.36N/A-$0.36N/AN/A5/13/2025Q1 2025CARMCarisma Therapeutics-$0.17-$0.22-$0.05-$0.22$2.47 million$3.65 million5/13/2025Q1 2025MBRXMoleculin Biotech-$0.71-$0.69+$0.02-$0.69N/AN/A5/8/2025Q1 2025DWTXDogwood Therapeutics-$0.77-$4.21-$3.44-$8.45N/AN/A4/11/2025Q4 2024TNFATNF PharmaceuticalsN/A-$0.66N/A-$0.66N/AN/A3/31/2025Q4 2024DWTXDogwood Therapeutics-$1.49-$6.29-$4.80-$6.29N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCARMCarisma TherapeuticsN/AN/AN/AN/AN/ADWTXDogwood TherapeuticsN/AN/AN/AN/AN/AMBRXMoleculin BiotechN/AN/AN/AN/AN/ATNFATNF PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCARMCarisma Therapeutics1.393.233.23DWTXDogwood TherapeuticsN/A1.711.71MBRXMoleculin BiotechN/A2.082.08TNFATNF PharmaceuticalsN/A1.721.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCARMCarisma Therapeutics44.27%DWTXDogwood Therapeutics9.05%MBRXMoleculin Biotech15.52%TNFATNF Pharmaceuticals9.64%Insider OwnershipCompanyInsider OwnershipCARMCarisma Therapeutics12.57%DWTXDogwood Therapeutics3.90%MBRXMoleculin Biotech1.90%TNFATNF Pharmaceuticals0.45%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCARMCarisma Therapeutics2041.79 million36.50 millionNo DataDWTXDogwood Therapeutics51.91 million1.17 millionN/AMBRXMoleculin Biotech2014.13 million3.86 millionNot OptionableTNFATNF Pharmaceuticals614.18 million2.72 millionN/ATNFA, CARM, MBRX, and DWTX HeadlinesRecent News About These CompaniesTNF Pharmaceuticals Amends Bylaws to Alter Voting RulesMay 9, 2025 | tipranks.comTNF Pharmaceuticals and Renova Health Report Positive Results in Identifying Targets for Treating TNF-Driven Inflammation in Patients Receiving GLP-1 AgonistsMay 8, 2025 | businesswire.comTNF Pharmaceuticals uses AI to refine patient selection for trialsApril 24, 2025 | uk.investing.comTNF Pharmaceuticals and Renova Health Utilize AI to Accelerate Drug DevelopmentApril 22, 2025 | finance.yahoo.comTNF Pharmaceuticals To Use AI To Recruit Patients For Drug Development: Retail Stays BearishApril 22, 2025 | msn.comTNF Pharmaceuticals Delivers Platform Presentation of Oral TNF-Alpha Inhibitor Isomyosamine at British Geriatrics Society’s Spring Meeting 2025April 17, 2025 | finance.yahoo.comTNF Pharmaceuticals, Inc. Common Stock (TNFA) Short InterestApril 3, 2025 | nasdaq.comTNF Pharmaceuticals faces Nasdaq delisting over priceMarch 23, 2025 | investing.comTNF Pharmaceuticals, Inc. Common StockMarch 20, 2025 | fxempire.comTNF Pharmaceuticals shares R&D progress on IsomyosamineMarch 12, 2025 | uk.investing.comTNF Pharmaceuticals initiates isomyosamine trialFebruary 25, 2025 | markets.businessinsider.comTNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha InhibitorFebruary 25, 2025 | businesswire.comTNFA stock touches 52-week low at $0.48 amid market challengesFebruary 14, 2025 | msn.comTNFA stock touches 52-week low at $1.02 amid market challengesJanuary 30, 2025 | msn.comHow Does TNF Pharmaceuticals Inc (TNFA) Stack Up Against Its Industry Peers?January 30, 2025 | bovnews.comTNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss TreatmentJanuary 29, 2025 | tmcnet.comTNF Pharmaceuticals to study TNF-alpha in patients taking GLP-1sJanuary 29, 2025 | markets.businessinsider.comTNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial ExpansionJanuary 15, 2025 | finance.yahoo.comTNF Pharmaceuticals, Inc. (TNFA)December 10, 2024 | au.finance.yahoo.comZeria Pharmaceutical gets grant for antibody binding to tumor necrosis factor alpha (tnfa)September 24, 2024 | pharmaceutical-technology.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTNFA, CARM, MBRX, and DWTX Company DescriptionsCarisma Therapeutics NASDAQ:CARM$0.45 -0.10 (-17.62%) Closing price 04:00 PM EasternExtended Trading$0.42 -0.03 (-6.78%) As of 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.Dogwood Therapeutics NASDAQ:DWTX$4.65 -0.53 (-10.23%) Closing price 04:00 PM EasternExtended Trading$4.67 +0.02 (+0.43%) As of 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.Moleculin Biotech NASDAQ:MBRX$0.64 -0.03 (-3.96%) Closing price 04:00 PM EasternExtended Trading$0.64 +0.00 (+0.16%) As of 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.TNF Pharmaceuticals NASDAQ:TNFA$0.14 -0.02 (-10.57%) Closing price 04:00 PM EasternExtended Trading$0.14 0.00 (0.00%) As of 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Analysts Love Lovesac, But Investors Should Be Cautious Oracle’s Cloud Boom Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
